Category: Vaccine

Additionally, the current price of the MVA-BN vaccine is out of reach for most low- and middle-income countries where mpox is endemic or is currently spreading. Therefore, the company that makes it, Bavarian Nordic, must review its pricing policy, and urgently seek partnership with one of the emerging vaccine manufacturers in Africa for a full and timely tech transfer so a vaccine protecting against a disease that is endemic to Africa can also be produced on the African continent in the future.

All relevant parties must also find a legal arrangement for any compensation that stems from the use of the MVA-BN vaccine in children and adolescents during this outbreak, such as a no-fault compensation fund. The pediatric use of MVA-BN was recommended by the United States CDC during the 2022 mpox outbreak and by the WHO Strategic Advisory Group of Experts on Immunization among children with increased risk of contracting mpox.

With the mpox outbreak in DRC continuing to evolve rapidly, the situation is urgent, Dr. Eyong said. Every necessary step must be taken to get mpox vaccines to the adults and children who need them now.

MSF is also calling for the WHO to accelerate the Emergency Use Listing (EUL) Procedure of the two mpox vaccines already approved by WHO-listed national regulatory authorities. EUL will encourage manufacturers to increase their production of the mpox vaccines, and allow Gavi, The Vaccine Alliance, and UNICEF to procure these vaccines for distribution.

MSF has been mobilizing emergency teams over the last couple months to respond to the mpox epidemic across DRC. They are on the ground in South Kivu, North Kivu, Equateur, and South Ubangi provinces to support the local health authorities. More than 1,159 patients have been treated since June 17.

Read more:

Mpox vaccine access must be dramatically increased - Doctors Without Borders (MSF-USA)

A new project aiming to accelerate the development and accessibility of human avian influenza (H5N1) messenger RNA (mRNA) vaccine candidates for manufacturers in low- and middle-income countries has been launched today. The Argentinian manufacturer Sinergium Biotech will lead this effort leveraging the World Health Organization (WHO) and the Medicines Patent Pool (MPP) mRNA Technology Transfer Programme.

The mRNA Technology Transfer Programme, jointly developed by WHO and MPP, was launched in July 2021 with the aim to build capacity in low- and middle-income countries (LMICs) for the development and production of mRNA-based vaccines. Sinergium Biotech, a partner in the mRNA Technology Transfer Programme, has developed candidate H5N1 vaccines and aims to establish proof-of-concept in preclinical models. Once the preclinical data package is concluded, the technology, materials, and expertise will be shared with other manufacturing partners, aiding the acceleration of the development of H5N1 vaccine candidates, and bolstering pandemic preparedness efforts.

"This initiative exemplifies why WHO established the mRNA Technology Transfer Programme to foster greater research, development and production in low- and middle-income countries, so that when the next pandemic arrives, the world will be better prepared to mount a more effective and more equitable response," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

"When we created the mRNA Technology Transfer Programme with WHO, our goal was to enable low- and middle-income countries to lead development efforts, foster collaboration, share resources, and disseminate knowledge, said Charles Gore, Executive Director of MPP. This project embodies our vision and demonstrates a strong commitment to future pandemic preparedness and response."

Avian influenza viruses are a significant public health risk due to their widespread circulation in animals and potential to cause a future pandemic. This development supplements ongoing work under the Pandemic Influenza Preparedness Framework to improve and strengthen the sharing of influenza viruses with human pandemic potential and increasing LMIC access to vaccines.

This announcement underscores the importance of not only geographically diversifying the innovation and production of health technologies including and recognizing the capacities in Latin American and the Caribbean, but also the importance of early planning for access and the sharing of knowledge and technologies during the research and development processes," said Dr Jarbas Barbosa, Director of the Pan American Health Organization.

Dr Alejandro Gil, Chief Executive Officer of Sinergium, said, "Sinergiums enhanced capacity and readiness to apply our expertise to H5N1 will play a vital role in this effort towards global pandemic preparedness. I would also like to thank PAHO who have also been instrumental through the strong support it offers to regional manufacturers in the Americas. We are excited to tackle this public health challenge and our R&D team will continue to work closely with the Programme Partners."

Excerpt from:

New initiative launched to advance mRNA vaccine development against human avian influenza (H5N1) - World Health Organization (WHO)

Press Release

Contacts: Tanya Espinosa (301) 851-4092 Suzanne Bond (301) 851-4070

WASHINGTON, July 29, 2024 The U.S. Department of Agricultures Animal and Plant Health Inspection Service (APHIS) today announced it will continue field assessment of the oral rabies vaccine (ORV) bait ONRAB in eight states as part of its larger-scale rabies management effort. This years field assessment will evaluate ONRABs distribution methods andeffectiveness in raccoons, skunks, and other wildlife.

Rabies is a serious public health concern. While rabies is almost always fatal once symptoms appear, it also is 100 percent preventable. Human exposures can be successfully remedied if medical attention is sought immediately following exposure. According to the Centers for Disease Control and Prevention (CDC), about 90 percent of reported rabies cases in the U.S. are in wildlife.

APHIS Wildlife Services (WS) leads the cooperative National Rabies Management Program that works to prevent the spread of rabies in wildlife. The program currently uses another rabies vaccine, RABORAL V-RG, to control the disease in raccoons, coyotes, and foxes. WS is also assessing the effectiveness of the ONRAB vaccine tomanage rabiesinraccoonsandskunks.

The ONRAB bait is a blister pack filled with the liquid vaccine and coated with a sweet attractant. When an animal bites into one of the baits, vaccine releases into their mouth and they develop immunity from rabies. Humans and pets cannot get rabies from contact with the bait but are asked to leave the bait undisturbed if they encounter it. If contact with bait occurs, the contact area should be immediately washed with warm water and soap. Each bait carries a toll-free number that people can call if they have additional questions concerning a bait contact.

Beginning in late July, WS and cooperators will distribute approximately 3.3 million ONRAB ORV baits by airplanes, helicopters, and vehicles in parts of Maine, New Hampshire, New York, Ohio, Pennsylvania, Vermont, and West Virginia to test the immune effects in targeted wildlife. Additionally, WS will distribute >73,000 ONRAB baits by helicopters and vehicles during October in parts of southern Tennessee to continue evaluating ONRABs effectiveness using these distribution methods. WS personnel will sample raccoons and skunks approximately 6-8 weeks following bait distribution to determine vaccinationrates.

Field assessment of ONRAB during 2024 is a collaborative effort among APHIS; the U.S. Department of Health and Human Services Centers for Disease Control and Prevention (CDC); the vaccine manufacturer (Artemis Technologies Inc., an indirect, wholly owned subsidiary of Ceva Sante Animale S.A., Guelph, Ontario, Canada); and State departments of agriculture, health, and natural resources.

Throughout the month of August, distribution of this ORV bait will span portions of:

During October, WS will distribute ONRAB baits in parts of Bradley, Hamilton, Marion, and Sequatchie counties in Tennessee.

For additional information concerning rabies or the ORV program, please visithttps://www.aphis.usda.gov/national-wildlife-programs/rabies or contact WS toll free at 1-866-4-USDA-WS(1-866-487-3297). To view a photo of the ONRAB vaccine bait, please visit:https://www.flickr.com/photos/usdagov/7780297536/in/album-72157623983143606/

APHIS protects the health of U.S. agriculture and natural resources against invasive pests and diseases, regulates genetically engineered crops, administers the Animal Welfare Act, and helps people and wildlife coexist. APHIS also certifies the health of U.S. agricultural exports and resolve phytosanitary and sanitary issues to open, expand, and maintain markets for U.S plant and animal products.

Read the original here:

USDA Continues Field Assessment of Oral Rabies Vaccine for Raccoons and other Wildlife - USDA APHIS

Fair Access

Delivery of first medical aid since Covid raises hopes that country could open up again to UN and aid agencies

Sun 28 Jul 2024 06.00 EDT

More than 4 million vaccine doses have been flown to Pyongyang, raising hopes that North Korea could open up again to UN agencies and NGOs amid reports of a worsening health situation in the authoritarian state.

The return of essential vaccines marks a significant milestone towards safeguarding childrens health and survival in this country, Roland Kupka, Unicefs acting representative for the Democratic Peoples Republic of Korea, said in a statement.

The vaccines include those against hepatitis B, polio, measles and tetanus, and were provided by Unicef, the World Health Organization and the vaccine alliance Gavi. Organisers say they are intended for 600,000 children and pregnant women who have missed out on vaccines since the Covid-19 pandemic. They are to be administered as part of a catch-up campaign in September by North Koreas public health ministry.

It follows numerous calls from the US and human rights groups for North Korea, considered one of the poorest countries in the world, to reopen its borders so vital aid can be delivered.

Almost all international aid workers had to leave during the Covid pandemic as the country shut its borders and tightened import controls. This diminished medicine and vaccine supplies as well as food imports, increasing malnutrition and leaving many including newborns vulnerable to deadly diseases such as tuberculosis and measles.

Prior to the pandemic, almost half of the population was undernourished and since then several floods and typhoons have hit the country, further jeopardising public health.

Earlier this month, the head of the UN Food and Agriculture Organization, Qu Dongyu, visited North Korea in a bid to reactivate the agencys relationship with the country and address food insecurity.

The reopening of the border and the return of Unicefs full team to DPR Korea will be critical to ensuring more essential support can be provided in 2024 and programmes can be scaled up as necessary to meet the needs of children and women, said Kupka. In 2019, Unicef had about 13 international staff in the country.

Ive got a feeling theyre going to open again to UN agencies and NGOs, said Nagi Shafik, who previously consulted for the UN on public health in North Korea, a country he described as fussy about their security.

Shafik said the North Korean government may have used the hiatus to consider how it would like to work with aid providers. It no longer wants to be regarded as a recipient of aid, Shafik said, but as more of a development partner.

They hate to be reliant on other people, he said, adding that they were open to ideas and wanted to be engaged on issues including health. North Korea was voted on to WHOs executive board last year. They are more open than people expect, Shafik said.

In the meantime, Kupka urged the North Korean government to facilitate the earliest possible return of humanitarian agency workers.

{{topLeft}}

{{bottomLeft}}

{{topRight}}

{{bottomRight}}

{{.}}

One-timeMonthlyAnnual

Other

Go here to read the rest:

Vaccine doses for 600,000 children and pregnant women flown to North Korea - The Guardian

The Brainy Insights

The market for zoster vaccines has increased due to the rising incidence of chickenpox in North America. Key players evolving in the zoster vaccine market are Merck & Co., Inc., Changchun BCHT Biotechnology Co, Vaccitech, Pfizer Inc, Jiangsu Recbio Technology Co., Ltd, GSK plc, SK chemicals, Geneone Life Science, CanSinoBIO, and Curevo Inc.

Newark, July 29, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 4.2 billionzoster vaccine market will reach USD 9.1 billion by 2033. The zoster vaccine market is driven by people's increasing understanding of how important vaccination is to preventing shingles. The global ageing population also fuels the market's expansion because shingles are more common in elderly persons. As an example, seroprevalence research conducted on Indian volunteers revealed that by the time they were 40 years old, over 90% of the participants carried this virus, making them susceptible to shingles. For individuals over 50, the Shingrix vaccination has been authorised to prevent both shingles and post-herpetic neuralgia. In addition, new and more potent vaccines and technological developments in vaccinations are anticipated to spur market expansion. Based on these indications, the market for zoster vaccines is expected to rise steadily over the next several years.

Request market scope and parent market analysis sample PDF: https://www.thebrainyinsights.com/enquiry/sample-request/14423

Key Insight of the Global Zoster Vaccine Market

North America will account for the largest market size during the forecast period.

The region's market is mostly driven by large players in North America, advantageous reimbursement practices, and high vaccination rates. In the United States, about 35% of eligible individuals have received vaccinations, whereas in Canada, over 20% do so. Additionally, public awareness and the region's recommendation for immunisation against the disease drive the market's growth over the projection period. Because of Shingrix's superior efficacy over Zostavax, the United States and Canada advise using it to prevent shingles in the elderly population.

The shingrix segment dominated the market, with a revenue of USD 1.76 billion.

The shingrix segment dominated the market, with the most significant revenue of USD 1.76 billion. The segment's growth can be ascribed to rising illness awareness and the approval of shingrix vaccines in different areas. For example, in May 2019, the National Medical Products Administration in China licensed shingrix as a shingles preventive.

Story continues

The recombinant vaccine segment dominated the market, with the most significant revenue of USD 2.43 billion.

The recombinant vaccine segment dominated the market, with the most significant revenue of USD 2.43 billion. The widespread use of shingrix throughout North America and Europe and the recombinant vaccine's great effectiveness in protecting adults against diseases drive the segment's growth.

Get a comprehensive report summary describing the market size and forecast: https://www.thebrainyinsights.com/enquiry/speak-to-analyst/14423

Market Dynamics:

Drivers: Increasing cases of herpes zoster worldwide

The ageing population compromised immune systems, and rising rates of chronic illnesses like HIV and cancer will all contribute to the global rise in the prevalence of herpes zoster disease, which will fuel the zoster vaccine market's expansion. Because more individuals are becoming aware of how important immunisation is to preventing shingles, there will likely be a rise in demand for zoster vaccine in the upcoming years.

Restraint: Limited vaccine uptake

In certain places, immunisation rates remain quite low despite strong recommendations. Misinformation, vaccination hesitancy, and adverse effect concerns impede market expansion.

Some of the major players operating in the zoster vaccine market are:

Merck & Co., Inc. Changchun BCHT Biotechnology Co Vaccitech Pfizer Inc Jiangsu Recbio Technology Co., Ltd GSK plc SK chemicals Geneone Life Science CanSinoBIO Curevo Inc

Key Segments cover in the market:

By Product:

SKYZoster Zostavax Shingrix

By Vaccine Type:

Live Attenuated Vaccine Recombinant Vaccine

Interested in Procure Data? Visit: https://www.thebrainyinsights.com/buy-now/14423/single

About the report:

The global zoster vaccine market is analyzed based on value (USD billion). All the segments have been analyzed on a worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes Porter's five forces model, attractiveness analysis, raw material analysis, supply, and demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D Head of Business Development Phone: +1-315-215-1633 Email: sales@thebrainyinsights.com Web: http://www.thebrainyinsights.com

See more here:

Zoster Vaccine Market to Reach $9.1 Billion by 2033; Increasing Cases of Herpes Zoster Drives the Market's Growth - Yahoo Finance

A recent study has suggested Shingrix, a relatively new vaccine given to protect older adults against shingles, may delay the onset of dementia.

This might seem like a bizarre link, but actually, research has previously shown an older version of the shingles vaccine, Zostavax, reduced the risk of dementia.

In this new study, published last week in the journal Nature Medicine, researchers from the United Kingdom found Shingrix delayed dementia onset by 17% compared with Zostavax.

So how did the researchers work this out, and how could a shingles vaccine affect dementia risk?

Shingles is a viral infection caused by the varicella-zoster virus. It causes painful rashes, and affects older people in particular.

Previously, Zostavax was used to vaccinate against shingles. It was administered as a single shot and provided good protection for about five years.

Shingrix has been developed based on a newer vaccine technology, and is thought to offer stronger and longer-lasting protection. Given in two doses, its now the preferred option for shingles vaccination in Australia and elsewhere.

In November 2023, Shingrix replaced Zostavax on the National Immunisation Program, making it available for free to those at highest risk of complications from shingles. This includes all adults aged 65 and over, First Nations people aged 50 and older, and younger adults with certain medical conditions that affect their immune systems.

Shingrix was approved by the US Food and Drugs Administration in October 2017. The researchers in the new study used the transition from Zostavax to Shingrix in the United States as an opportunity for research.

They selected 103,837 people who received Zostavax (between October 2014 and September 2017) and compared them with 103,837 people who received Shingrix (between November 2017 and October 2020).

By analysing data from electronic health records, they found people who received Shingrix had a 17% increase in diagnosis-free time during the follow-up period (up to six years after vaccination) compared with those who received Zostavax. This was equivalent to an average of 164 extra days without a dementia diagnosis.

The researchers also compared the shingles vaccines to other vaccines: influenza, and a combined vaccine for tetanus, diphtheria and pertussis. Shingrix and Zostavax performed around 1427% better in lowering the risk of a dementia diagnosis, with Shingrix associated with a greater improvement.

The benefits of Shingrix in terms of dementia risk were significant for both sexes, but more pronounced for women. This is not entirely surprising, because we know women have a higher risk of developing dementia due to interplay of biological factors. These include being more sensitive to certain genetic mutations associated with dementia and hormonal differences.

The idea that vaccination against viral infection can lower the risk of dementia has been around for more than two decades. Associations have been observed between vaccines, such as those for diphtheria, tetanus, polio and influenza, and subsequent dementia risk.

Research has shown Zostavax vaccination can reduce the risk of developing dementia by 20% compared with people who are unvaccinated.

But it may not be that the vaccines themselves protect against dementia. Rather, it may be the resulting lack of viral infection creating this effect. Research indicates bacterial infections in the gut, as well as viral infections, are associated with a higher risk of dementia.

Notably, untreated infections with herpes simplex (herpes) virus closely related to the varicella-zoster virus that causes shingles can significantly increase the risk of developing dementia. Research has also shown shingles increases the risk of a later dementia diagnosis.

The mechanism is not entirely clear. But there are two potential pathways which may help us understand why infections could increase the risk of dementia.

First, certain molecules are produced when a baby is developing in the womb to help with the bodys development. These molecules have the potential to cause inflammation and accelerate ageing, so the production of these molecules is silenced around birth. However, viral infections such as shingles can reactivate the production of these molecules in adult life which could hypothetically lead to dementia.

Second, in Alzheimers disease, a specific protein called Amyloid- go rogue and kill brain cells. Certain proteins produced by viruses such as COVID and bad gut bacteria have the potential to support Amyloid- in its toxic form. In laboratory conditions, these proteins have been shown to accelerate the onset of dementia.

With an ageing population, the burden of dementia is only likely to become greater in the years to come. Theres a lot more we have to learn about the causes of the disease and what we can potentially do to prevent and treat it.

This new study has some limitations. For example, time without a diagnosis doesnt necessarily mean time without disease. Some people may have underlying disease with delayed diagnosis.

This research indicates Shingrix could have a silent benefit, but its too early to suggest we can use antiviral vaccines to prevent dementia.

Overall, we need more research exploring in greater detail how infections are linked with dementia. This will help us understand the root causes of dementia and design potential therapies.

See the article here:

Could the shingles vaccine lower your risk of dementia? - The Conversation Indonesia

World Health Organization. Immunization, Vaccines and Biologicals. (2019).

World Health Organization. Immunization Coverage. (2019).

Mihigo, R. et al. Challenges of immunization in the African region. Pan Afr. Med. J. 27(Suppl 3), 12 (2017).

PubMed PubMed Central Google Scholar

Ethiopia, C. S. A. Mini Ethiopian Demographic Health Survey. (Addis Ababa, 2019).

Addis Declaration on Immunization. Accessed 2020.

Brownwright, T. K., Dodson, Z. M. & van Panhuis, W. G. Spatial clustering of measles vaccination coverage among children in sub-Saharan Africa. BMC Public Health 17(1), 957 (2017).

Article PubMed PubMed Central Google Scholar

Tefera, Y. A. et al. Predictors and barriers to full vaccination among children in Ethiopia. Vaccines 6(2), 22 (2018).

Article PubMed PubMed Central Google Scholar

Wado, Y. D., Afework, M. F. & Hindin, M. J. Childhood vaccination in rural southwestern Ethiopia: The nexus with demographic factors and womens autonomy. Pan Afr. Med. J. 17(Suppl 1), 9 (2014).

PubMed PubMed Central Google Scholar

Yenit, M., Assegid, S. & Abrha, H. Factors associated with incomplete childhood vaccination among children 1223 months of age in Machakel Woreda, East Gojjam Zone: A case-control study. J. Pregnancy Child Health 2(4), 180 (2015).

Google Scholar

Tesfaye, T. D., Temesgen, W. A. & Kasa, A. S. Vaccination coverage and associated factors among children aged 1223 months in Northwest Ethiopia. Hum. Vaccines Immunother. 14(10), 23482354 (2018).

Article Google Scholar

Workina, A., Seid, S. & Moga, T. T. Reason for incomplete vaccination and associated factors among children aged 1223 months in Serbo Town, Jimma Zone, Oromia Region, Southwest Ethiopia. Adv. Res. J. Multi-Discipl. Discov. I 32(14), 7984 (2018).

Google Scholar

Tesfaye, F. et al. Predictors of Immunization defaulting among children age 1223 months in Hawassa Zuria district of Southern Ethiopia. Int. J. Public Health Sci. 3(3), 185193 (2014).

Google Scholar

Tessema, F. et al. Child vaccination coverage and dropout rates in pastoral and semi-pastoral regions in Ethiopia: CORE group polio project implementation areas. Ethiop. J. Health Dev. 33 (2019).

Asar, S. et al. PRISMA; preferred reporting items for systematic reviews and meta-analyses. J. Rafsanjan Univ. Med. Sci. 15(1), 6880 (2016).

Google Scholar

EPHPP, P. Quality assessment tool for quantitative studies. Hamilton: The effective public health practice project. URL: http://www.ephpp.ca/PDF/Quality%20Assessment. 20 (2010).

Methods, N. C. C. F. & Tools. A quality assessment tool for quantitative studies. (McMaster University Hamilton, 2008).

Thomas, H., Ciliska, D. & Dobbins, M. Quality assessment tool for quantitative studies (Effective Public Health Practice Project McMaster University, 2003).

Google Scholar

Porritt, K., Gomersall, J. & Lockwood, C. JBIs systematic reviews: Study selection and critical appraisal. AJN Am. J. Nurs. 114(6), 4752 (2014).

Article PubMed Google Scholar

Institute, J. B. The Joanna Briggs institute critical appraisal tools for use in JBI systematic reviews checklist for analytical cross-sectional studies. North Adelaide, Austr. Joanna Briggs Inst. (2017).

Hedges, L. V. & Vevea, J. L. Fixed-and random-effects models in meta-analysis. Psychol. Methods 3(4), 486 (1998).

Article Google Scholar

Harris, R. J. et al. Metan: fixed-and random-effects meta-analysis. Stata J. 8(1), 328 (2008).

Article Google Scholar

Gandrud, C. Reproducible research with R and R studio (CRC Press, 2013).

Book Google Scholar

Health, F. D. R. O. E. M. O. HSTP health sector transformation plan 2015/162019/20 (20082012 EFY). Federal Democratic Republic of Ethiopia Ministry of Health (2015).

Thorlund, K. et al. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PloS One 7(7), e39471 (2012).

Article ADS CAS PubMed PubMed Central Google Scholar

Pathak, M. et al. Which is the preferred measure of heterogeneity in meta-analysis and why? A revisit. Biostat. Biom. Open Access J. 1, 17 (2017).

Google Scholar

Duval, S. & Tweedie, R. Trim and fill: a simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2), 455463 (2000).

Article CAS PubMed Google Scholar

Sterne, J. A. C., Becker, B. J. & Egger, M. The funnel plot. In Publication bias in metaanalysis: Prevention, assessment and adjustments (eds Rothstein, H. R. et al.) 7398 (Wiley, 2005). https://doi.org/10.1002/0470870168.ch5.

Chapter Google Scholar

Bogale, T. Assessment of incomplete vaccination and associated risk factors among children under one year at Guder hospital, West Shoa zone, Oromia regional state, Ethiopia. Assessment 45 (2017).

Negussie, A. et al. Factors associated with incomplete childhood immunization in Arbegona district, southern Ethiopia: A case-control study. BMC Public Health 16(1), 27 (2015).

Article Google Scholar

Yismaw, A. E. et al. Incomplete childhood vaccination and associated factors among children aged 1223 months in Gondar city administration, Northwest, Ethiopia 2018. BMC Res. Notes 12(1), 241 (2019).

Article PubMed PubMed Central Google Scholar

Asfaw, A. G. et al. Determinants of default to full completion of immunization among children aged 12 to 23 months in south Ethiopia: Unmatched case-control study. Pan Afr. Med. J. 23(1) (2016).

Gualu, T. & Dilie, A. Vaccination coverage and associated factors among children aged 1223 months in Debre Markos Town, Amhara regional state, Ethiopia. Adv. Public Health 2017, 16 (2017).

Article Google Scholar

Tamirat, K. S. & Sisay, M. M. Full immunization coverage and its associated factors among children aged 1223 months in Ethiopia: Further analysis from the 2016 Ethiopia demographic and health survey. BMC Public Health 19(1), 1019 (2019).

Article PubMed PubMed Central Google Scholar

Yenit, M. K., Gelaw, Y. A. & Shiferaw, A. M. Mothers health service utilization and attitude were the main predictors of incomplete childhood vaccination in east-central Ethiopia: A case-control study. Arch. Public Health 76(1), 14 (2018).

Article Google Scholar

Lakew, Y., Bekele, A. & Biadgilign, S. Factors influencing full immunization coverage among 1223 months of age children in Ethiopia: evidence from the national demographic and health survey in 2011. BMC Public Health 15(1), 728 (2015).

Article PubMed PubMed Central Google Scholar

Hailu, S. et al. Low immunization coverage in Wonago district, southern Ethiopia: A community-based cross-sectional study. PloS one 14(7), e0220144 (2019).

Article CAS PubMed PubMed Central Google Scholar

Wassihun, B. Determinants of incomplete immunization among children age 1223 months in Southwest, Ethiopia: Case control study.

Roy, S. G. Risk factors for childhood immunization incompletion in Ethiopia. (2010).

Birhane, M. G. N., Mekonnen, M. & Jember, A. A community-based assessment of the immunization coverage and the associated factors of children aged 1223 months at Gondar Town, Northwest Ethiopia. (2015).

Lake, M. W. et al. Factors for low routine immunization performance: a community-based cross-sectional study in Dessie town, south Wollo zone, Ethiopia, 2014. Adv. Appl.Sci. 1(1), 717 (2016).

ADS Google Scholar

Girmay, A. & Dadi, A. F. Full immunization coverage and associated factors among children aged 1223 months in hard-to-reach areas of Ethiopia. Int. J. Pediatr. 2019, 18 (2019).

Article Google Scholar

Mohammed, R. T. Assessment of factors associated with incomplete immunization among children aged 1223 months in Ethiopia. (2016).

Kassahun, M. B., Biks, G. A. & Teferra, A. S. Level of immunization coverage and associated factors among children aged 1223 months in Lay Armachiho District, North Gondar Zone, Northwest Ethiopia: A community-based cross-sectional study. BMC Res. Notes 8(1), 239 (2015).

Article PubMed PubMed Central Google Scholar

Mesfin, M. Incomplete vaccination and associated factors among children aged 1223 months in Yirgalem Town, South Ethiopia. (Addis Abeba Universty, 2015).

Mekonnen, A. G., Bayleyegn, A. D. & Ayele, E. T. Immunization coverage of 1223 months old children and its associated factors in Minjar-Shenkora district, Ethiopia: A community-based study. BMC Pediatr. 19(1), 198 (2019).

Article PubMed PubMed Central Google Scholar

Geweniger, A. & Abbas, K. M. Childhood vaccination coverage and equity impact in Ethiopia by socioeconomic, geographic, maternal and child characteristics. Vaccine 38(20), 36273638 (2020).

Article PubMed PubMed Central Google Scholar

Hagos, M. G. et al. Magnitude and associated factors of delayed immunization among children aged 1123 months in Edagahamus town, Tigray, Ethiopia. (2018).

Legesse, E. & Dechasa, W. An assessment of child immunization coverage and its determinants in Sinana District, Southeast Ethiopia. BMC Pediatr. 15(1), 31 (2015).

Article PubMed PubMed Central Google Scholar

Regassa, N., Bird, Y. & Moraros, J. Preference in the use of full childhood immunizations in Ethiopia: The role of maternal health services. Patient Prefer. Adher. 13, 91 (2019).

Article Google Scholar

Zewdie, T. Maternal knowledge, involvement and integrative early child development programs in Ethiopia. Ethiop. J. Educ. 22(1), 5784 (2002).

Google Scholar

Huang, K.-Y. et al. Maternal knowledge of child development and quality of parenting among White, African-American and Hispanic mothers. J. Appl. Dev. Psychol. 26(2), 149170 (2005).

Article Google Scholar

Reich, S. What do mothers know? Maternal knowledge of child development. Infant Ment. Health J. Off. Publ. World Assoc. Infant Ment. Health 26(2), 143156 (2005).

Google Scholar

Sundaram, M. S., Sekar, M. & Subburaj, A. Women empowerment: Role of education. Int. J. Manag. Soc. Sci. 2(12), 7685 (2014).

Google Scholar

McMillin, S. E. et al. The role of maternal knowledge of child development in predicting risk for child maltreatment. Clin. Pediatr. 55(4), 374376 (2016).

Article Google Scholar

Ojobo, J. A. Education: A catalyst for women empowerment in Nigeria. Ethiop. J. Educ. Sci. 4(1) (2008).

Murphy-Graham, E. And when she comes home? Education and womens empowerment in intimate relationships. Int. J. Educ. Dev. 30(3), 320331 (2010).

Article Google Scholar

Murtaza, K. F. Women empowerment through higher education in Gilgit-Baltistan. Int. J. Acad. Res. Bus. Soc. Sci. 2(9), 343 (2012).

Google Scholar

Upadhyay, U. D. & Karasek, D. Womens empowerment and ideal family size: an examination of DHS empowerment measures in Sub-Saharan Africa. Int. Perspect. Sex. Reprod. Health 38, 7889 (2012).

Article PubMed Google Scholar

View post:

Effect of maternal education on completing childhood vaccination in Ethiopia: systematic review and meta-analysis - Nature.com

The roll-out of the RTS,S and R21 vaccines against malaria marks a turning point in the millennia-old battle against this deadly infection. Both vaccines work by targeting the same protein on the surface of malaria parasites and are expected to have a substantial impact on reducing malaria cases and deaths in children.

Interpreting their efficacy numbers a measure of how much a vaccine protects people against disease under controlled trial conditions can be challenging. This is because these measurements are not directly comparable due to differences in study design and contexts using different approaches to provide the vaccine, measuring the vaccines effect over varying lengths of time or in areas with differing malaria burden.

RTS,S vaccine clinical trials were conducted in many sites and have seven years of follow-up data, which means far more is known about RTS,S efficacy in different settings, and how long the protection it provides lasts for. Efficacy results for the R21 vaccine are based on 12 months of follow-up and fewer study sites.

Heres a summary of what we know about the efficacy of malaria vaccines so far.

The large-scale phase 3 trial of the RTS,S vaccine evaluated its efficacy from 2009 to 2014 across 11 different study sites in seven countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. These sites represent a range of malaria transmission intensities across sub-Saharan Africa . A substantial number of malaria cases were prevented in all countries when children were vaccinated in an age-based approach: the children received three vaccine doses starting from around 5 months of age, plus a fourth dose to prolong protection around age 2.

The RTS,S vaccine reduced the number of malaria cases by half (51%) during the year following vaccination, and this included in study sites in low and high-transmission areas.

A later trial of RTS,S using a different vaccination strategy found that, for countries with highly seasonal patterns of malaria transmission, giving the initial three vaccine doses before the start of the peak rainy season (seasonal administration) was even more efficacious at 72% over the first year. Additional booster doses administered each year just prior to subsequent malaria seasons prolonged the protection.

The phase 3 clinical trial of the R21 vaccine started in 2019, and was conducted in five study sites in four countries Burkina Faso, Mali, Kenya and Tanzania. This trial evaluated an age-based vaccination approach in three of the study sites and seasonal vaccination in two study sites. Similar to RTS,S, when given in an age-based approach, R21 reduced clinical malaria by 66% in the 12 months following vaccination.

Age-based vaccination in the R21 trial included study sites in low to moderate transmission areas but did not include sites with year-round high transmission settings.

Similar to the RTS,S seasonal vaccination trial, when the R21 vaccine was provided just before the malaria season in areas of seasonal transmission, malaria episodes were reduced by 75% in the first year following vaccination.

Of particular importance to countries aiming to roll out the vaccine is the fact that, while both RTS,S and R21 studies have shown that efficacy is improved when using a seasonal approach, running public health campaigns to deliver vaccines seasonally is much more complex to implement in practice compared to an age-based approach where vaccines are given to children through the routine system at childhood immunisation clinics.

Results from the large-scale RTS,S study showed that lower transmission areas tended to have higher efficacy numbers, but the vaccine achieved higher impact in reducing malaria cases in high transmission areas, where the burden is highest.

This is important because neither malaria vaccine provides complete protection against infection . Both vaccines target malaria parasites during the sporozoite stage of their lifecycle the point where they first enter the human body and begin replicating in liver cells.

In areas and time periods with high transmission, the immune system is under a significant assault due to repeated biting from mosquitos, says Dr W. Scott Gordon, Head of Gavis Malaria Vaccine Programme. Each bite can transmit as many as 1,000 sporozoites, so even a very small proportion of those getting through can result in the immunised child still coming down with malaria, and lower measured efficacy from the vaccine.

This is one reason why WHO prioritises the use of malaria vaccines in moderate to high transmission areas, where public health impact is expected to be highest, says Dr Lindsey Wu, Technical Officer at the WHO Global Malaria Programme.

Malaria is most dangerous during the first year of life.

The longer-term follow-up of RTS,S efficacy shows waning of protection over time, which is also shown for other vaccines like COVID-19 vaccines. Children continue to benefit from the RTS,S vaccine over seven years of follow-up.

Even with moderate efficacy, the currently recommended malaria vaccines provide protection to children during the most vulnerable time of their life, says Wu.

We dont know what the duration of protection with R21 is, because it hasnt been studied for long enough yet, said Prof Brian Greenwood, at the London School of Hygiene and Tropical Medicine, UK, who has been involved in phase 3 trials of both vaccines. R21 clinical trials are ongoing.

Not all children who fall sick from malaria develop severe illness, but for those that do, the consequences can be dire, with death sometimes occurring within 2448 hours from the start of symptoms, which usually start within 1015 daysof infection.

Pilot introductions of the RTS,S vaccine, through the Malaria Vaccine Implementation Programme, vaccinated more than 2 million children in Ghana, Kenya and Malawi from 2019 to 2023. The evaluation of the large-scale roll-out measured a substantial reduction in severe malaria, and 13% drop in deaths from all causes among children age-eligible for vaccination.

While clinical trials are useful for measuring vaccine efficacy, it was through the pilot implementation of RTS,S, where the vaccine was rolled out into a larger population through routine health systems, that we were really able to measure effectiveness in a real-world setting and say this had high public health impact, says Wu.

For R21, the overall levels of severe malaria and death in the phase 3 trial were too low to measure the effect that the malaria vaccine had on these outcomes.

So, where does this leave us?

The bottom line is that there are now two safe and effective malaria vaccines available in Africa that will ensure millions more children will have access to this malaria prevention.

With more than 600,000 deaths from malaria each year the vast majority among African children under the age of five wide roll-out of both vaccines is expected to save tens of thousands of lives each year.

Go here to see the original:

How effective are malaria vaccines? - Gavi, the Vaccine Alliance

COLUMBIA Ahead of the 2024-25 school year, the South Carolina Department of Public Health (DPH) reminds parents to make sure their children are up to date with all required vaccines and to familiarize themselves with the updated School and Childcare Exclusion ListChildren enrolled in school and childcare are required to be current on certain vaccinations at the start of each school year. This helps protect the health of children, teachers and school staff who are in group settings every day, as vaccines are one of the most-successful public health interventions for reducing disease spread and safeguarding against vaccine-preventable illnesses and complications.

Vaccines are a safe and effective way of protecting our children from diseases like chicken pox, whooping cough, mumps and measles, said Dr. Brannon Traxler, DPH Deputy Director for Health Promotion and Services and Chief Medical Officer. Appointment slots will fill up quickly before the school year starts, so parents are urged to schedule an appointment as early as possible to ensure your child is up to date on required and recommended vaccinations and they dont miss school for not meeting requirements.

To find a vaccine provider near you, visit DPHs Find a Vaccines for Children Provider tool. Appointments for immunizations can also be made at many of DPHs county health departments by calling 1-855-472-3432 or online using Web Chat.

Current vaccination requirements for the 2024-25 school year are available on the DPH website. Updates for this school year include:

None of these are newly required vaccines; the changes reflect the fact that more grade levels are being added.

While COVID-19 and flu vaccines are not required, DPH and the CDC continue to recommend that everyone 6 months and older receive their COVID-19 and flu vaccination to protect themselves and others. Flu vaccines for the current season typically become available in late September in many pharmacies, and an updated COVID-19 vaccine is also expected in the fall.

During the past school year, there were 294 outbreaks of vaccine preventable diseases reported from school and childcare settings, 290 of which were due to COVID-19 or influenza. The low number of other vaccine-preventable outbreaks shows the effectiveness of the vaccines required for attendance in schools and childcare settings. However, there were 1,023 individual cases of vaccine-preventable diseases other than COVID-19 and influenza reported statewide, indicating the risk these diseases pose to the entire community.

Although deaths and complications are not always reportable, we know these are avoidable consequences from these diseases, said Dr. Linda Bell, DPH Health Programs Branch Director and State Epidemiologist.

To help protect children from unnecessary exposure to contagious or infectious diseases, South Carolina requires that children and staff with certain diseases and conditions stay home from school or childcare while contagious.

Each year, DPH also publishes the School and Childcare Exclusion List, which explains how long ill children and staff should stay out of school or childcare, and what is needed before the child/student or employee is permitted to return. The updated 2024-2025 list is available online in both English and Spanish.

We dont want children to miss school because of illness, but its important to protect every child in the classroom by requiring those who are sick to stay home until it is safe to return, Traxler said. A very important step for keeping kids in school is preventing infections, and making sure your child receives immunizations and washes his or her hands often. These protective measures also help protect the entire community from disease spread.

Go here to read the rest:

DPH reminds parents to get children vaccinated ahead of upcoming school year - The Post and Courier

Health experts said vaccinations should be at the top of the back to class check list.

TOLEDO, Ohio It's required for all kids in Ohio to get up to date on immunizations before school starts.

If your child needs their shots updated, you are in luck. Appointments are now open with the Toledo-Lucas County Health Department.

The Shots 4 Tots n Teens clinics are held up to 5 days a week, Monday through Friday, and everyone in need is encouraged to attend no matter their cir'cumstances.

"My suggestion is to start early with planning for back to school," said Angie Bauman, the executive director of nursing with the Lucas County Health Department. "We know that the rush comes in August and September even into the beginning of October and it makes it really hard to get those kids in for appointments. So, starting earlier makes a big difference."

Bauman said deadlines around the school year can make the process more stressful which is why they encourage families to make appointments make a plan come early and come prepared.

"We don't want people coming up against deadlines and not be able to get into their doctor's office," said Bauman. "Or having to come here and have a long wait to be seen, it really is more convenient to schedule it when it's convenient for parents and families so they can come in on their own time without feeling the rush and get it done in a more relaxed environment."

Clinics are held on site at both the Health Department and at local libraries. Clinic dates and times are subject to changes.

The Heather Downs library and Holland branch libraries host walk-ins.

The shot clinics serve all students from babies all the way up to age 18. There are also opportunities for adults to get vaccinated.

Before you attend any shot clinic it is recommended to have a copy of your child's shot records.

You can find more information about different vaccines HERE.

Continue reading here:

Local health expert urges parents to visit back to school vaccine clinics - WTOL